Loading
companiesCompany
ARCH Venture Partners
A Chicago venture firm that starts and funds science-heavy biotech companies. Several of its companies work on cancer drugs, cancer cell therapies and cancer diagnostics.
Overview
ARCH Venture Partners was founded in 1986 (Wikipedia) and describes its mission as 'catalyzing discoveries that prevent, detect, and cure disease', with offices in Chicago and Seattle. Its model is company creation from academic science, often taking large early stakes and syndicating later rounds with crossover funds. Oncology is a recurring theme on the portfolio page: Agios Pharmaceuticals (gene-targeted cancer therapeutics, Nasdaq: AGIO), Akamis Bio (systemic immune oncology therapies), Arsenal Biosciences (programmable cell cancer therapies), Carrick Therapeutics, Erasca (AI-driven cancer drug discovery, Nasdaq: ERAS), Boundless Bio (ecDNA-directed therapies) and Elephas Biosciences (cancer diagnostics) are all listed.
Portfolio (4)
Filter the startups table| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| Arsenal Biosciences South San Francisco, CA, US | cell therapy | Renal cell carcinomaOvarian cancer | none on record | |
| Boundless Bio San Diego, CA, US | Public | biotech | HR-positive / HER2-negative breast cancerTriple-negative breast cancer (TNBC) | IPO 2024, $100M |
| Erasca San Diego, CA, US | Public | biotech | Colorectal cancerGlioma & glioblastoma | IPO 2021, $345M |
| GRAIL Menlo Park, CA, US | Public | diagnostics | none on record |